Platinum-Based Therapy in Adenosquamous Pancreatic Cancer: Experience at Two Institutions
Adenosquamous carcinoma of the pancreas is a rare type of pancreatic cancer. Although its molecular biology profile has been shown to be similar to pancreatic ductal adenocarcinoma tumors, it has different prognostic features. There is no consensus or guidelines to treat this tumor differently from pancreatic adenocarcinoma, but therapies based on gemcitabine and platinum chemotherapeutics such as cisplatin and oxaliplatin have been used based on results of a few case reports. We discuss the Abstract #269 from the 2014 ASCO Gastrointestinal Cancers Symposium showing better outcomes from platinum-based therapy in this type of tumors. Triggered by this study, we also present our experience. Prospective studies to investigate the clinical outcomes from platinum-based therapy and the role of target therapies such as erlotinib are warranted.
Image: Pancreatic carcinoma stained for Dpc4 suppressor gene
Christine G. Simone, Tania Zuluaga Toro, Ellie Chan, Thomas J. Characteristics and outcomes of adenosquamous carcinoma of the pancreas. J Clin Oncol 30: 2012 (suppl 34; abstr 311)
Trikudanathan G, Dasanu CA. Adenosquamous carcinoma of the pancreas: a distinct clinicopathologic entity. South Med J. 2010 Sep;103(9):903-10 PMID: 
Okabayashi T, Hanazaki K. Surgical outcome of adenosquamous carcinoma of the pancreas. World J Gastroenterol. 2008 Nov 28 ;14(44):6765-70 PMID: 
Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS. 415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival. J Surg Res. 2012 May 1;174(1):12-9. PMID:
Jonathan R. Brody, Christina L. Costantino, Magdalena Potoczek, Joseph Cozzitorto, Peter McCue, Charles J. Yeo, Ralph H. Hruban, Agnieszka K. Witkiewicz. Adenosquamous Carcinoma of the Pancreas Harbors KRAS2, DPC4 and TP53 Molecular Alterations Similar to Pancreatic Ductal Adenocarcinoma. Mod Pathol. 2009;22(5):651-659. PMID: 
David E Kardon, Lester D.R Thompson, Ronald M Przygodzki and Clara S Heffess. Adenosquamous Carcinoma Of The Pancreas: A Clinicopathologic Series Of 25 Cases. Mod Pathol 2001;14(5):443–451. PMID: 
Yamaue H, Tanimura H, Onishi H, Tani M, Kinoshita H, Kawai M, Yokoyama S, Uchiyama K. Adenocarcinoma of the pancreas: successful treatment with extended radical surgery, intraoperative radiation therapy, and locoregional chemotherapy. Int J Pancreatol. 2001;29(1):53-8. PMID: .
Shibagaki K, Fujita K, Nakayama S, Takenaka M, Fukuba N, Matsui S, Ozaka M, Yoshinaga H, Masuzawa A, Watanabe A, Fujiwara H, Sugawara A, Fujita T, Mukai H, Kinoshita Y. Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy. Int J Clin Oncol. 2008 Feb;13(1):74-7. PMID: .
Tanaka N, Ohoida J, Matuno T, Gouchim A, Iwagaki H, Moreira LF, Orita K. Response of adenosquamous carcinoma of the pancreas to interferon-alpha, tumor necrosis factor-alpha and 5-fluorouracil combined treatment. Anticancer Res. 1994 Nov-Dec;14(6B):2739-42. PMID:
Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg. 2004 Oct;28(10):1011-8. PMID:
Aaron Tyler Wild, Avani Satish Dholakia, Katherine Yu-Ting Fan, Rachit Kumar, Daniel A. Laheru, Lei Zheng, et al. Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas. J Clin Oncol 32, 2014 (suppl 3; abstr 269)
Copyright (c) 2014 Andre Luiz De Souza, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.